We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PhRMA Calls on USPTO to Reconsider Patent Eligibility
PhRMA Calls on USPTO to Reconsider Patent Eligibility
PhRMA is urging the USPTO to reevaluate patent eligibility for prescription drugs to provide the drug industry a better framework for interpreting regulations and recent case law.